New syncytial virus alert from Italian neonatologists

The propagation of respiratory syncytial virus (RSV) represents a significant concern among medical experts, with particular attention paid to the impact on infants within the first six months of life, where the virus has the potential to manifest in cases of bronchiolitis, even in severe forms. In the past year, approximately 15,000 hospitalisations for bronchiolitis caused by RSV were recorded, with 3,000 of these cases requiring intensive care. The mortality rate associated with this condition was 16 deaths. Consequently, Italian Society of Neonatology President Luigi Orfeo has recommended the implementation of prophylaxis beginning in November for all newborns, utilizing the monoclonal antibody Nirsevimab-Beyfortus. This has been demonstrated to reduce the risk of hospitalisation in this age group by 90%. The monoclonal antibody Nirsevimab-Beyfortus is a preventive antibody that blocks the penetration of the virus into the body. It is often incorrectly referred to as a vaccine. The Ministry of Health has initiated contact with AIFA to make this drug, also known as an anti-bronchiolitis vaccine, accessible in all regions at the expense of the National Health Service.